ES2239032T3 - Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso. - Google Patents
Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso.Info
- Publication number
- ES2239032T3 ES2239032T3 ES00957617T ES00957617T ES2239032T3 ES 2239032 T3 ES2239032 T3 ES 2239032T3 ES 00957617 T ES00957617 T ES 00957617T ES 00957617 T ES00957617 T ES 00957617T ES 2239032 T3 ES2239032 T3 ES 2239032T3
- Authority
- ES
- Spain
- Prior art keywords
- binding agent
- muc
- tumor
- use according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US149492P | 1999-08-18 | ||
| US16471499P | 1999-11-11 | 1999-11-11 | |
| US164714P | 1999-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2239032T3 true ES2239032T3 (es) | 2005-09-16 |
Family
ID=26846783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00957617T Expired - Lifetime ES2239032T3 (es) | 1999-08-18 | 2000-08-18 | Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (https=) |
| JP (2) | JP2003519096A (https=) |
| AT (1) | ATE290879T1 (https=) |
| AU (1) | AU782569B2 (https=) |
| DE (1) | DE60018761T2 (https=) |
| ES (1) | ES2239032T3 (https=) |
| WO (1) | WO2001012217A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| CA2432276A1 (en) | 2000-12-22 | 2002-08-01 | Dana-Farber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| EP1357944B1 (en) * | 2001-01-30 | 2007-06-13 | Altachem Pharma Ltd. | Perylenequinones for use with immunotherapy agents |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| ES2424131T3 (es) | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
| GB2397018B (en) * | 2001-10-26 | 2006-05-31 | Altarex Medical Corp | Combination therapy for treating disease |
| KR100978126B1 (ko) * | 2002-01-24 | 2010-08-26 | 반즈 쥬이쉬 하스피털 | 인테그린 표적화 조영제 |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| PL1896051T3 (pl) | 2005-06-28 | 2015-04-30 | Oncothyreon Inc | Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1) |
| WO2007016762A1 (en) | 2005-08-10 | 2007-02-15 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| JP5773352B2 (ja) | 2008-10-28 | 2015-09-02 | 塩野義製薬株式会社 | 抗ｍｕｃ１抗体 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| EP2565268A4 (en) | 2010-04-28 | 2013-10-09 | Shionogi & Co | NEW MUC1 ANTIBODY |
| KR20140023903A (ko) | 2011-02-24 | 2014-02-27 | 온코타이레온, 인코포레이티드 | 항원보강제를 갖는 muc1 기초 당지질펩티드 백신 |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0636029B1 (en) * | 1992-04-13 | 2000-11-08 | Dana-Farber Cancer Institute, Inc. | Antibodies specific for carcinoma-associated antigens |
| EP0649532B1 (en) * | 1992-07-06 | 1997-11-12 | Biomira, Inc. | Photoactivation of proteins for conjugation purposes |
| WO1994011508A2 (en) * | 1992-11-13 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| ATE233102T1 (de) * | 1996-05-15 | 2003-03-15 | Altarex Inc | Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten |
| EP1015033A2 (en) * | 1997-01-10 | 2000-07-05 | AltaRex, Corp. | Substituted perylenequinones for use in photodynamic therapy |
| CA2319688A1 (en) * | 1998-02-13 | 1999-08-19 | Gunther Bastert | Specific antibodies against mammary tumor-associated mucin, method for production and use |
-
2000
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
- 2000-08-18 EP EP00957617A patent/EP1204423B1/en not_active Expired - Lifetime
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en not_active Ceased
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE60018761T2 (de) | 2006-02-02 |
| AU782569B2 (en) | 2005-08-11 |
| EP1204423A1 (en) | 2002-05-15 |
| DE60018761D1 (de) | 2005-04-21 |
| JP2012046518A (ja) | 2012-03-08 |
| EP1204423B1 (en) | 2005-03-16 |
| WO2001012217A1 (en) | 2001-02-22 |
| WO2001012217A9 (en) | 2002-06-27 |
| JP2003519096A (ja) | 2003-06-17 |
| ATE290879T1 (de) | 2005-04-15 |
| AU6921100A (en) | 2001-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2239032T3 (es) | Anticuerpo terapeutico contra el antigeno muc-1 y metodos para su uso. | |
| US6716966B1 (en) | Therapeutic binding agents against MUC-1 antigen and methods for their use | |
| US7147850B2 (en) | Therapeutic binding agents against MUC-1 antigen and methods for their use | |
| US7090844B2 (en) | Use of antibodies against the MUC18 antigen | |
| TWI504408B (zh) | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 | |
| US7067131B2 (en) | Methods for using anti-MUC18 antibodies | |
| US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
| JP7408559B2 (ja) | プラチナベースの薬剤と抗組織因子抗体－薬物コンジュゲートの組み合わせを用いるがんの治療方法 | |
| US20050019324A1 (en) | Peptides and antibodies to muc 1 proteins | |
| KR20190125398A (ko) | 글리칸-상호작용 화합물 및 사용 방법 | |
| KR20160020421A (ko) | 항-folr1 면역접합체 투약 섭생 | |
| TW201726175A (zh) | 新穎抗密連蛋白（ｃｌａｕｄｉｎ）抗體及使用方法 | |
| EP0556285A1 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| WO1999040119A1 (es) | Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene | |
| CA3023088A1 (en) | Novel anti-tnfrsf21 antibodies and methods of use | |
| JP7127021B2 (ja) | 細胞傷害性粒子 | |
| JP2018515457A (ja) | カリケアマイシン構築物および使用方法 | |
| ES2293751B1 (es) | Composiciones terapeuticas que alteran la respuesta inmune (alt-014pc). | |
| WO2004106379A1 (en) | Immunotherapy of rectal cancer | |
| Oldham et al. | Individually specified drug immunoconjugates in cancer treatment | |
| CA2380936A1 (en) | Therapeutic antibody against muc-1 antigen and methods for their use | |
| US20040265318A1 (en) | Use of antibodies for the vaccination against cancer | |
| AU650080B2 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents |